Oral breast cancer wins a wider gesture than the Food and Drug Administration for ESR1

(MEDPAGE today)-The Food and Drug Administration (FDA) has agreed to IMLUNESTRANT (Inluriyo) of advanced/metastatic/previously treated breast cancer. Approval stipulates the use of adults with …